In a major D2C news India development within the rapidly expanding D2C wellness startups segment, ZeroHarm Sciences has raised ₹65 crore (approximately $7.15 million) in a Series A funding round. The round was led by Kotak Alternate Asset Managers Limited, through its Kotak Life Sciences Fund I, which invested ₹40 crore, while Alkemi Growth Capital invested ₹25 crore. For those tracking D2C daily news, D2C startup news, and Indian D2C updates, this funding marks a strong validation of science-led Direct-to-consumer India brands operating at the intersection of Ayurveda and advanced technology.
Founded in 2020 by Sachin Darbarwar and Shweta Darbarwar, the Hyderabad-based company develops plant-based health supplements using proprietary nano formulation technology. Positioned among the Latest D2C startups redefining preventive healthcare, ZeroHarm Sciences aims to build India’s first “Trust over Promise” health platform—where supplement efficacy is backed by measurable consumer health outcomes rather than marketing claims.
Within the D2C ecosystem India, the nutraceutical category is witnessing rapid investor interest as D2C market trends 2025 increasingly favor outcome-driven wellness solutions. ZeroHarm’s core differentiation lies in converting plant-based nutrients into nano-sized particles to enhance bioavailability and enable controlled release at lower dosages. By integrating Ayurveda with advanced nano-science, the company is building a differentiated D2C business model India in preventive wellness.
The ₹65 crore Series A will be deployed toward national brand building, international expansion across the USA, the UK, and the Middle East, and scaling research and manufacturing capabilities. This aligns with aggressive D2C expansion plans and positions ZeroHarm among VC-backed D2C brands targeting global markets. As D2C funding rounds continue to spotlight wellness innovation, the brand’s international push strengthens its D2C startup valuation narrative within the broader Direct-to-consumer startup IPO tracker conversation.
ZeroHarm controls its value chain end-to-end, sourcing medicinal plants through a network of over 10,000 farmers across Northeast India and the Himalayas. The company has filed and received patents for nano formulations covering turmeric-based phytochemicals, iron folic acid combinations, carotenoid-based eye health, and synbiotic gut health compositions—strengthening its intellectual property moat within D2C industry news discussions around sustainable D2C brands and Ayurveda D2C products.
The brand currently offers over 60 SKUs across categories including diabetes management, heart health, joint care, immunity, gut health, oncology support, women’s wellness, and performance nutrition. Products are distributed through its D2C platform, Amazon, Flipkart, and quick commerce D2C channels, serving more than 300,000 customers to date. This omnichannel D2C strategy reinforces its D2C retail vs ecommerce balance and scalable D2C go-to-market strategy.
India’s nutraceutical market is projected to reach $18 billion by 2025, while the global market is expected to cross $720 billion by 2027—creating a significant runway for D2C revenue growth. Competing with brands such as Kapiva, Plix, HealthKart, and Wellbeing Nutrition, ZeroHarm is positioning itself as a premium D2C brand India focused on science-backed efficacy rather than trend-driven formulations.
For observers following India’s D2C market news and insights and D2C brands scaling in 2025, ZeroHarm Sciences’ ₹65 crore Series A underscores growing private equity in D2C and investor confidence in capital-efficient, IP-led D2C wellness startups within the fast-evolving Direct-to-consumer India ecosystem.
